Loading...
Intas Pharmaceuticals Limited — Paclitaxel Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #3 for Paclitaxel · $5.9M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #3 Indian exporter of Paclitaxel with $5.9M in export value and 405 verified shipments. Intas Pharmaceuticals Limited holds a 7.1% market share in Paclitaxel exports across 19 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $2.2M | 68 | 40.0% |
| CANADA | $567.9K | 21 | 10.5% |
| UNITED KINGDOM | $453.7K | 18 | 8.4% |
| NETHERLANDS | $453.5K | 47 | 8.4% |
| MEXICO | $436.1K | 13 | 8.0% |
| FRANCE | $357.2K | 9 | 6.6% |
| POLAND | $282.0K | 28 | 5.2% |
| SOUTH AFRICA | $239.4K | 8 | 4.4% |
| ITALY | $212.5K | 121 | 3.9% |
| SPAIN | $78.5K | 9 | 1.4% |
Intas Pharmaceuticals Limited exports Paclitaxel to 19 countries. The largest destination is BRAZIL accounting for 40.0% of Intas Pharmaceuticals Limited's Paclitaxel shipments, followed by CANADA (10.5%) and UNITED KINGDOM (8.4%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD FARMACUTICA LTDA. | BRAZIL | $968.2K | 29 |
| ACCORD FARMACUTICA LTDA | BRAZIL | $519.5K | 19 |
| ACCORD FARMACUTICA LIMITEDA | BRAZIL | $503.1K | 16 |
| ACCORD UK | UNITED KINGDOM | $384.6K | 11 |
| ACCORD FARMA S A DE C V | MEXICO | $339.1K | 9 |
| XXCORXXHEAXXHCAXX B XX | FRANCE |
India exported $61.4M worth of Paclitaxel through 4,928 shipments from 319 suppliers to 142 countries, serving 959 buyers globally. Intas Pharmaceuticals Limited contributes $5.9M to this total, accounting for 7.1% of India's Paclitaxel exports. Intas Pharmaceuticals Limited ships Paclitaxel to 19 countries through 63 buyers.
Intas Pharmaceuticals Limited's average Paclitaxel shipment value is $14.7K per consignment, based on 405 shipments totaling $5.9M. The largest destination is BRAZIL (40.0% of Intas Pharmaceuticals Limited's Paclitaxel exports).
Intas Pharmaceuticals Limited ranks #3 among 319 Indian Paclitaxel exporters with a 7.1% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($25.1M), MSN LABORATORIES PRIVATE LIMITED ($6.9M), INTAS PHARMACEUTICALS LIMITED ($5.9M). Intas Pharmaceuticals Limited processed 405 shipments to 19 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI PACLITAXEL INJ USP 6 | $838.8K | 27 |
| PHARMACEUTICAL DRUGS AND MEDICINE :ACOEXCEL 300MG/50ML INJ. 1X1 VIAL E1 EACH ML CONTAINS PACLITAXEL USP...6.00MG ETHAN | $221.2K | 6 |
| PHARMA DRUGS & MEDI PACLITAXEL INJ USP 6MG/ML, 16.7ML VIAL AS PER INVOICEVLS | $181.0K | 6 |
| PHARMA DRUGS AND MEDI PACLITAXEL INJ USP | $153.8K | 5 |
| PACLITAXEL 6MG/ML 100ML P1ACO-FRANCE | $150.7K | 6 |
| PHARMA DRUGS & MEDI PACLITAXEL INJ,6MG/M | $141.1K | 3 |
| PHARMA DRUGS AND MEDI PACLITAXEL INJ USP6MG/ML, 50ML VIAL AS PER INVVLS | $140.1K | 4 |
| PHARMA DRUGS AND MEDI PACLITAXEL INJ USP6MG/ML, 50ML VIAL AS PER INV | $115.0K | 5 |
What Intas Pharmaceuticals Limited must comply with to export Paclitaxel to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED | $25.1M | 854 | 24 | $29.4K |
| 2 | MSN LABORATORIES PRIVATE LIMITED | $6.9M | 138 | 2 | $50.0K |
| 3 | INTAS PHARMACEUTICALS LIMITED ★ | $5.9M | 405 | 19 | $14.7K |
| 5 | PANACEA BIOTEC PHARMA LIMITED | $3.3M |
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 830 | 16.8% |
| SAHAR AIR | 614 | 12.5% |
| DELHI AIR | 599 | 12.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 554 | 11.2% |
| HYDERABAD AIR | 186 | 3.8% |
| AHEMDABAD AIR | 183 | 3.7% |
| Bombay Air | 172 | 3.5% |
| HYDERABAD ACC (INHYD4) | 160 | 3.2% |
Intas Pharmaceuticals Limited also exports these oncology products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Paclitaxel, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Paclitaxel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Paclitaxel exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
| $300.0K |
| 6 |
| ACCORD HEALTHCARE INC. | CANADA | $267.8K | 9 |
| ACCORD HEALTHCARE INC | CANADA | $175.3K | 7 |
| TO THE ORDER | ITALY | $141.1K | 34 |
| BROCACEF NL : DUTCH | NETHERLANDS | $136.5K | 10 |
Intas Pharmaceuticals Limited supplies Paclitaxel to 63 buyers globally. The largest buyer is ACCORD FARMACUTICA LTDA. (BRAZIL), followed by ACCORD FARMACUTICA LTDA (BRAZIL) and ACCORD FARMACUTICA LIMITEDA (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| PHARMA DRUG&MED:PACLITAXEL INJ USP 6MG/M | $105.4K | 5 |
| PACLITAXEL 6MG/ML 100ML P1(ACO-FRANCE | $100.3K | 4 |
Intas Pharmaceuticals Limited exports 241 distinct Paclitaxel formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI PACLITAXEL INJ USP 6 with 27 shipments worth $838.8K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 65 |
| 15 |
| $50.0K |
| 6 | VENUS REMEDIES LIMITED | $3.2M | 220 | 18 | $14.4K |
Intas Pharmaceuticals Limited ranks #3 among 319 Indian Paclitaxel exporters. Average shipment value of $14.7K compared to the market average of $192.6K. The closest competitors by value are FRESENIUS KABI ONCOLOGY LIMITED and MSN LABORATORIES PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 142+ countries, 959+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Paclitaxel. For current shipment-level data, contact TransData Nexus.